| 1.77 0.01 (0.57%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.48 | 1-year : | 3.06 |
| Resists | First : | 2.12 | Second : | 2.61 |
| Pivot price | 1.83  |
|||
| Supports | First : | 1.32 | Second : | 1.09 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.82 |
| MA(100) : | 1.6 |
MA(250) : | 1.81 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 11.5 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 2.63 | Low : | 1.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IPHA ] has closed above bottom band by 38.4%. Bollinger Bands are 21.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.79 - 1.8 | 1.8 - 1.81 |
| Low: | 1.74 - 1.75 | 1.75 - 1.76 |
| Close: | 1.76 - 1.77 | 1.77 - 1.78 |
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Fri, 22 May 2026
Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus - Stock Titan
Thu, 21 May 2026
Outcome of Innate Pharma’s 2026 Annual General Meeting - Yahoo Finance
Tue, 19 May 2026
Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026 - Stock Titan
Sat, 16 May 2026
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Fri, 15 May 2026
Innate Pharma S.A. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IPHA) 2026-05-15 - Seeking Alpha
Thu, 14 May 2026
Innate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 246 (K) |
| Shares Short P.Month | 64 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | 0 % |
| Operating Margin | -689.6 % |
| Return on Assets (ttm) | -38.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -46.8 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.77 |
| PEG Ratio | 0 |
| Price to Book value | -6.56 |
| Price to Sales | 18.44 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|